image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 11.22
-3.79 %
$ 652 M
Market Cap
11.02
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one EMBC stock under the worst case scenario is HIDDEN Compared to the current market price of 11.2 USD, Embecta Corp. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one EMBC stock under the base case scenario is HIDDEN Compared to the current market price of 11.2 USD, Embecta Corp. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one EMBC stock under the best case scenario is HIDDEN Compared to the current market price of 11.2 USD, Embecta Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EMBC

image
$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
1.12 B REVENUE
0.21%
167 M OPERATING INCOME
-24.70%
78.3 M NET INCOME
11.22%
35.7 M OPERATING CASH FLOW
-47.27%
-15.8 M INVESTING CASH FLOW
40.38%
-73.4 M FINANCING CASH FLOW
-50.72%
262 M REVENUE
-8.46%
28.7 M OPERATING INCOME
9.54%
-26.3 M NET INCOME
-180.14%
-5.3 M OPERATING CASH FLOW
-19.92%
-1.5 M INVESTING CASH FLOW
0.00%
-45.2 M FINANCING CASH FLOW
-23.50%
Balance Sheet Embecta Corp.
image
Current Assets 761 M
Cash & Short-Term Investments 268 M
Receivables 248 M
Other Current Assets 246 M
Non-Current Assets 524 M
Long-Term Investments 0
PP&E 290 M
Other Non-Current Assets 234 M
20.81 %19.30 %19.10 %22.59 %18.20 %Total Assets$1.3b
Current Liabilities 374 M
Accounts Payable 91 M
Short-Term Debt 12.9 M
Other Current Liabilities 270 M
Non-Current Liabilities 1.65 B
Long-Term Debt 1.6 B
Other Non-Current Liabilities 54.1 M
4.50 %13.35 %78.84 %Total Liabilities$2.0b
EFFICIENCY
Earnings Waterfall Embecta Corp.
image
Revenue 1.12 B
Cost Of Revenue 388 M
Gross Profit 735 M
Operating Expenses 568 M
Operating Income 167 M
Other Expenses 88.5 M
Net Income 78.3 M
1b1b1b1b800m800m600m600m400m400m200m200m001b(388m)735m(568m)167m(88m)78mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.46% GROSS MARGIN
65.46%
14.85% OPERATING MARGIN
14.85%
6.97% NET MARGIN
6.97%
-10.61% ROE
-10.61%
6.09% ROA
6.09%
31.97% ROIC
31.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Embecta Corp.
image
500m500m450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00202020202021202120222022202320232024202420252025
Net Income 78.3 M
Depreciation & Amortization 36.2 M
Capital Expenditures -15.8 M
Stock-Based Compensation 26.3 M
Change in Working Capital -47.7 M
Others 96.7 M
Free Cash Flow 19.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Embecta Corp.
image
Wall Street analysts predict an average 1-year price target for EMBC of $19.3 , with forecasts ranging from a low of $12 to a high of $26 .
EMBC Lowest Price Target Wall Street Target
12 USD 6.95%
EMBC Average Price Target Wall Street Target
19.3 USD 72.31%
EMBC Highest Price Target Wall Street Target
26 USD 131.73%
Price
Max Price Target
Min Price Target
Average Price Target
26262424222220201818161614141212101088Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.74% DIVIDEND YIELD
0.15 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.700.700.600.600.500.500.400.400.300.300.200.200.100.100.000.000.150.150.150.150.150.150.150.150.150.600.150.600.150.450.0020222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Embecta Corp.
image
Sold
0-3 MONTHS
50.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
178 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
embecta to Report Fiscal Second Quarter 2025 Financial Results PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. globenewswire.com - 1 week ago
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. globenewswire.com - 1 month ago
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. seekingalpha.com - 2 months ago
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET. globenewswire.com - 2 months ago
Embecta Corp. (EMBC) Q1 2025 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q1 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - President & Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Ryan Schiller - Wolfe Research Operator Good day, and thank you for standing by. Welcome, ladies and gentlemen, to the Embecta Fiscal First Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 months ago
Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.61 per share a year ago. zacks.com - 2 months ago
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. globenewswire.com - 2 months ago
embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. globenewswire.com - 2 months ago
embecta to Report Fiscal First Quarter 2025 Financial Results PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. globenewswire.com - 3 months ago
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog. zacks.com - 3 months ago
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR. zacks.com - 3 months ago
3 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue. zacks.com - 3 months ago
8. Profile Summary

Embecta Corp. EMBC

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 652 M
Dividend Yield 0.74%
Description Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Contact 300 Kimball Drive, Parsippany, NJ, 07054 https://www.embecta.com
IPO Date March 22, 2022
Employees 2100
Officers Mr. Anthony M. Roth Vice President, Chief Accounting Officer & Corporate Controller Ms. Ginny Blocki Senior Vice President of Global Marketing & Product Management Mr. Pravesh Khandelwal Vice President & Head of Investor Relations Ms. Colleen Riley Senior Vice President & Chief Technology Officer Mr. Tom Blount Senior Vice President & President of North America Mr. Jeffrey Z. Mann Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary Ms. Jean M. Casner Senior Vice President & Chief Human Resources Officer Mr. Shaun Curtis Senior Vice President of Global Manufacturing & Supply Chain Mr. Jacob P. Elguicze Senior Vice President & Chief Financial Officer Mr. Devdatt Kurdikar Ph.D. President, Chief Executive Officer & Director